NCT05753267CompletedPhase 2/3
Fenofibrate in Ulcerative Colitis
Clinical Study to Evaluate the Possible Efficacy of Fenofibrate in Patient With Ulcerative Colitis
Source: ClinicalTrials.gov · Last updated 4 May 2026
Brief summary (registry, in English)
Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia. Apart from their metabolic action, anti-inflammatory properties of fibrates have been described, including inhibition of NF-kappa B signaling and pro-inflammatory cytokine production. 4 Fenofibrate, an important peroxisome proliferator-activated receptor-a (PPAR- α) agonist, is widely used in clinical as a triglyceride (TG)-lowering agent.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 22 Feb 2023
- Start date
- 28 Feb 2023
- Primary completion date
- 20 Sept 2025
- Lead sponsor
- Tanta University
- Diseases
- Ulcerative colitis
- NCT number
- NCT05753267
What you commit to
- Study type: Interventional · Phase 2/3
- Participants enrolled: 60
- From 28 Feb 2023 to the primary completion date, 20 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients taking rectal or systemic steroids
- Patients taking immunosuppressives or biological therapies
- Addiction to alcohol and/or drugs
Other illness
- Colorectal cancer patients
- Other inflammatory bowel diseases (CD).
- Known allergy to the Fenofibrate
Other
- Breastfeeding
- Significant liver and kidney function abnormalities
- Patients with severe UC
Who the study is looking for
- Age ≥ 18 years
- Both males and females will be included
- Negative pregnancy test and effective contraception.
- Mild and moderate UC patients diagnosed and confirmed by an endoscope
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tanta Unuversity Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
Related publications
- Therapeutic Modulation of IL-6/STAT-3 and Nitric Oxide by Fenofibrate in Patients With Ulcerative Colitis: A Randomized Controlled Pilot Study.Pharmacotherapy · 2025 · PMID 41330887
This page is information, not medical advice. Discuss any trial with your doctor.